世界卫生组织全球癌症临床试验概览
该综述基于世界卫生组织国际临床试验注册平台1999年至2022年12月注册的89069项全球癌症临床试验,揭示癌症临床试验格局由高收入国家主导且集中于药物干预,跨国合作仅见于3%的招募中试验;肝癌、胃癌、胰腺癌和宫颈癌等最致命癌症在非洲和东南亚持续缺席研究热点。
要点
- 全球癌症临床试验由高收入国家主导,药物干预占主导地位。
- 跨国合作仅占招募中试验的3%。
- 肝癌、胃癌、胰腺癌和宫颈癌在非洲和东南亚持续缺席研究热点。
核心结论
- 全球癌症临床试验格局由高收入国家主导且聚焦药物干预,跨国合作有限,部分最致命癌症在研究热点中持续缺席,尤其在非洲和东南亚。
研究设计与样本
- 综述基于世界卫生组织国际临床试验注册平台(ICTRP)1999年至2022年12月注册的89069项全球癌症临床试验进行回顾分析。
主要发现
- 1999年至2022年12月,世界卫生组织国际临床试验注册平台共注册89069项全球癌症临床试验。
- 癌症临床试验格局由高收入国家主导,并集中于药物干预。
- 跨国合作仅见于3%的招募中试验。
- 肝癌、胃癌、胰腺癌和宫颈癌等最致命癌症在非洲和东南亚持续缺席研究最多的癌症类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials are essential to advancing cancer control, yet access and participation remain unequal globally. The World Health Organization (WHO) established the International Clinical Trials Registry Platform (ICTRP) to enable a complete view of interventional clinical research for all those involved in healthcare decision-making and to identify actionable goals to equitable participation at the global level. A review of 89,069 global cancer clinical trials registered in the WHO ICTRP between 1999 and December 2022 revealed a cancer clinical trial landscape dominated by high-income countries and focused on pharmacological interventions, with multinational collaboration limited to only 3% of recruiting trials. Several of the deadliest cancers, including liver, stomach, pancreas and cervical cancer, were consistently missing from the top most-studied cancer types, particularly in Africa and Southeast Asia. In this Review, we summarize the key findings of the WHO global landscape review and discuss strategies to act on these data, which provide critical empirical evidence to inform policy, practice and investment decisions.
引用
- Casolino R, Tatah L, Charnaud S, et al. The WHO global landscape of cancer clinical trials. Nat Med. 2025. PMID: 40926101. doi:10.1038/s41591-025-03926-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。